Regenicin, Inc. (RGIN)

Regenicin Cash Flow Statement

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Mar 31, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020	Sep 30, 2019	Sep 30, 2018
Net Income	-0.93	-0.64	-0.67	-0.56	-0.76	-0.56
Loss (Gain) From Sale of Investments	0	0	0	0	0	-
Stock-Based Compensation	-	-	-	-	0.03	-
Other Operating Activities	0.04	0.04	0.03	-0.11	-	-0.25
Change in Accounts Payable	-0.09	0.01	0.01	0.1	0.06	0.04
Change in Other Net Operating Assets	0.28	0.56	0.61	0.44	0.4	0.68
Operating Cash Flow	-0.7	-0.03	-0.02	-0.12	-0.27	-0.1
Short-Term Debt Issued	-	0.04	0.02	0.12	0.13	0.12
Total Debt Issued	0.02	0.04	0.02	0.12	0.13	0.12
Short-Term Debt Repaid	-	-	-	-	-0.02	-0.04
Total Debt Repaid	-	-	-	-	-0.02	-0.04
Net Debt Issued (Repaid)	0.02	0.04	0.02	0.12	0.12	0.08
Financing Cash Flow	-0.96	0.04	0.02	0.12	0.12	0.08
Net Cash Flow	10.88	0.01	0	0	-0.15	-0.02
Cash Interest Paid	-	-	-	-	0	0
Levered Free Cash Flow	12.18	0.21	0.23	-0.01	0.19	-0.08
Unlevered Free Cash Flow	12.21	0.23	0.25	0.02	0.2	-0.07
Change in Net Working Capital	-12.76	-0.61	-0.65	-0.43	-0.63	-0.43

Source: S&P Global Market Intelligence. Standard template. Financial Sources.